Literature DB >> 2745932

Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis.

R Candrina1, B Cerudelli, V Braga, A Salvi.   

Abstract

We examined the effects of the acute administration of salmon calcitonin on phosphate metabolism in tumoral calcinosis. On two different days, 200 MRC U of the synthetic hormone were administered sc to a 38-year-old patient, either as twice daily 100 MRC U injections, or as a continuous sc infusion via a portable pump. Both ways of calcitonin administration elicited a phosphaturic effect and a lowering of serum phosphate level comparable with that observed after an iv infusion of calcitonin. 1,25 dihydroxyvitamin D level, which was in the normal range during a control study, increased after calcitonin administration. In our patient, long term therapy with diet, a phosphate-binding agent and calcitonin prevented the occurrence of new ectopic calcifications. Owing to its phosphaturic activity, synthetic salmon calcitonin may be a useful adjunct to diet and aluminium-containing antacids in long-term management of tumoral calcinosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2745932     DOI: 10.1007/BF03349921

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  9 in total

1.  Treatment of tumoral calcinosis with phosphorus deprivation.

Authors:  G Mozaffarian; F W Lafferty; O H Pearson
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

2.  Developmental abnormalities of the dentine and pulp associated with tumoral calcinosis.

Authors:  I P Hunter; D G MacDonald; M M Ferguson
Journal:  Br Dent J       Date:  1973-11-20       Impact factor: 1.626

3.  Simultaneous measurement of 1.25-dihydroxy-vitamin D, 24.25-dihydroxy-vitamin D and 25-hydroxy-vitamin D from a single two milliliters serum specimen. Preliminary clinical application.

Authors:  D Tartarotti; S Adami; G Galvanini; R Dorizzi; G Piemonte; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

4.  Phosphaturic action of calcitonin in pseudotumoral calcinosis.

Authors:  A Salvi; B Cerudelli; A Cimino; F Zuccato; G Giustina
Journal:  Horm Metab Res       Date:  1983-05       Impact factor: 2.936

5.  Calcium and phosphate metabolism in tumoral calcinosis.

Authors:  P D Mitnick; S Goldfarb; E Slatopolsky; J Lemann; R W Gray; Z S Agus
Journal:  Ann Intern Med       Date:  1980-04       Impact factor: 25.391

6.  Hyperphosphatemic tumoral calcinosis: effects of phosphate depletion on vitamin D metabolism, and of acute hypocalcemia on parathyroid hormone secretion and action.

Authors:  E G Lufkin; R Kumar; H Heath
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

7.  Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity.

Authors:  K W Lyles; E J Burkes; G J Ellis; K J Lucas; E A Dolan; M K Drezner
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

8.  Tumoral calcinosis: evidence for concurrent defects in renal tubular phosphorus transport and in 1 alpha,25-dihydroxycholecalciferol synthesis.

Authors:  J E Zerwekh; L A Sanders; J Townsend; C Y Pak
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

9.  Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25-dihydroxycholecalciferol concentrations.

Authors:  M J Prince; P C Schaeffer; R S Goldsmith; A B Chausmer
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

  9 in total
  7 in total

Review 1.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

Review 2.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

Review 3.  The changing face of hypophosphatemic disorders in the FGF-23 era.

Authors:  Janet Y Lee; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

4.  Tumoral calcinosis-like lesion of the proximal linea aspera.

Authors:  L L Seeger; D L Butler; J J Eckardt; L Layfield; J S Adams
Journal:  Skeletal Radiol       Date:  1990       Impact factor: 2.199

Review 5.  Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.

Authors:  Lisal J Folsom; Erik A Imel
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

6.  Differential response of idiopathic sporadic tumoral calcinosis to bisphosphonates.

Authors:  Karthik Balachandran; Sadishkumar Kamalanathan; Jaya Prakash Sahoo; Ashok Kumar Das; Dhanapathi Halanaik
Journal:  Indian J Endocrinol Metab       Date:  2014-07

Review 7.  Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.

Authors:  Alison M Boyce; Alisa E Lee; Kelly L Roszko; Rachel I Gafni
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-08       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.